AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653.
The applications WO2008103126 and WO2009011653, respectively, claim: i) Combinations of a spirocyclic piperidine chemokine CCR1 antagonist with a corticosteroid, and their use for the treatment of asthma and chronic obstructive pulmonary disease. ii) Processes for the preparation of a spirocyclic piperidine derivative, a chemokine CCR1 antagonist. These applications point to the preferred compound being a development compound. The evidence for this compound being AZD-4818, a chemokine CCR1 antagonist that was in Phase II development for the treatment of chronic obstructive pulmonary disease, is reviewed in the light of these and earlier patents relating to it.
Norman
Peter
P
Norman Consulting, 18 Pink lane, Burnham, Bucks, SL1 8JW, UK. petrosn@bigfoot.com
D000818:Animals; D001249:Asthma / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D010330:Patents as Topic; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D054389:Receptors, CCR1 / Q000037:antagonists & inhibitors*; D013141:Spiro Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
C546512:AZD-4818; C515300:CCR1 protein, human; D005938:Glucocorticoids; D010880:Piperidines; D054389:Receptors, CCR1; D013141:Spiro Compounds